Trevena

edit

Trevena is focused on the identification of novel GPCR drugs with unique biology designed to deliver high levels of efficacy and/or low side effect potential.

Milestones

edit

• Received $24M in Series A funding. (3/08)
  Posted 6/17/09 at 6:23pm
• Michael W. Lark, Senior Vice President and Head, Research added.
  Posted 6/17/09 at 6:23pm
• Mark Strobeck, Chief Business Officer added.
  Posted 6/17/09 at 6:23pm
• Maxine Gowen, President and CEO added.
  Posted 6/17/09 at 6:23pm
• Dennis Yamashita, Vice President and Head, Chemistry added.
  Posted 6/17/09 at 6:23pm

Videos

Screenshots

edit

Above: Homepage
Uploaded: 6/18/09

Sources

1. Trevena, Inc. Announces $24 Million Series A Financing (trevenainc.com) [edit]